BIIB241213P160000
- 4.50
- +0.60+15.38%
Biogen Newsroom
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can XAI, Nvidia Help Stabilize Trajectory?
MicroStrategy Stock Could Get Added to the Nasdaq 100 Because of a Quirk
Biogen Reinstated With a Neutral at BofA
BofA Restarts Coverage of 11 Large-cap Biopharmas
B of A Securities Reinstates Neutral on Biogen, Announces $178 Price Target
Biogen Cut at Jefferies as '2025 Has a Tough Setup'
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Biogen Analyst Ratings
Jefferies Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $180
Biogen's Modest Growth Prospects and Revenue Challenges Highlighted in Hold Rating
Express News | Biogen : Jefferies Cuts to Hold From Buy
Biogen Appoints Tim Power as Head of Investor Relations
Stocks With Best Odds of Risk-adjusted Returns Deserve Attention: Goldman Sachs
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Biogen (BIIB) and Edwards Lifesciences (EW)
Morgan Stanley Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $192
GeneDx Announces Biogen, Praxis Precision Medicines And Stoke Therapeutics As The Founding Partners To Its Patient Access Program For Pediatric Epilepsy, Which Provides Access To Whole Exome Sequencing.
Express News | Biogen Inc : Morgan Stanley Cuts Target Price to $192.00 From $204.00
Biogen Says Leqembi Got Approval to Treat Early Alzheimer's Disease in Mexico
Express News | "Leqembi®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico